Entrada Therapeutics, Inc. Common Stock (TRDA) is a publicly traded Healthcare sector company. As of May 21, 2026, TRDA trades at $6.18 with a market cap of $228.65M and a P/E ratio of -1.49. TRDA moved +6.73% today. Year to date, TRDA is -42.48%; over the trailing twelve months it is -26.70%. Its 52-week range spans $4.93 to $21.79. Analyst consensus is strong buy with an average price target of $19.50. Rallies surfaces TRDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
TRDA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TRDA recently traded at $6.18. Market cap is $228.65M. P/E ratio is -1.49. Revenue is $5.74M.
| Metric | Value |
|---|---|
| Price | $6.18 |
| Market Cap | $228.65M |
| P/E Ratio | -1.49 |
| EPS | $-3.99 |
| Dividend Yield | 0.00% |
| 52-Week High | $21.79 |
| 52-Week Low | $4.93 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $5.74M |
| Net Income | $-166.12M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $25.42M | $-143.75M | $-3.47 |
| 2023 | $129.01M | $-6.68M | $-0.20 |
| 2022 | $0 | $-94.62M | $-3.02 |
| 2021 | $0 | $-51.16M | $-8.16 |
8 analysts cover TRDA: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.50.